ArticleThe Journal of clinical and aesthetic dermatology2025
Refractory Acrodermatitis Continua of Hallopeau in a Pediatric Patient: Unveiling Underlying Mixed Connective Tissue Disorder.
Article in The Journal of clinical and aesthetic dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acrodermatitis continua of Hallopeau (ACH) is a rare pustular psoriasis variant that presents as sterile pustules on the hands and feet with a relapsing course. This condition is not easily treated, but literature shows some cases are successfully controlled with biologics such as etanercept, adalimumab, secukinumab, and ustekinumab. Mixed connective tissue disease (MCTD) is a type of autoimmune disease and is rarely seen in the pediatric population. It is characterized by overlapping features of various autoimmune disorders, often involving scleroderma, systemic lupus erythematosus, polymyositis, and other organ dysfunction. MCTD is typically diagnosed with lab testing to indicate the presence of specific autoantibodies to a nuclear matrix protein, such as ribonucleoprotein. This communication emphasizes the importance of revisiting diagnoses in patients with persistent, refractory skin conditions and highlights the need for comprehensive evaluation in the presence of evolving or atypical presentations, especially when autoimmune diseases are suspected. Steps for diagnostic workup and treatment may provide clinical benefits to patients and serve as a reference for other clinicians. The course of treatment for ACH and MCTD in the pediatric and adolescent population is discussed.
Indexed as
Identifiers
40575601PMC12189215What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.